Consistently, ELISA assay showed that EVs acquired from IDO1-overexpression ovarian cancer cells significantly increased the L-kyn level in the endothelial cells, and these effects were reversed by treatment with GW4869, a classical EV inhibitor (Fig. 8b). Here, IDO1 is linked to ovarian cancer.